

Partnering for a Purpose – Our Patients.

THE PARTNERSHIP

Clinical development of ONIVYDE® (irinotecan liposome injection) in 2nd line metastatic pancreatic cancer.

INSIDE THE DEAL

Commercialization and clinical development for ONIVYDE® is pioneered by Ipsen in the United States, while Servier leads the commercial efforts outside of the United States and Taiwan under an exclusive licensing agreement with Ipsen.

FROM PURPOSE TO PROMISE

- Two global biopharmaceutical leaders dedicated to improving patients' lives through innovative medicines and with the help of healthcare professionals.
- Focused on advancing access to non-communicable disease prevention, treatment and care in low- and middle-income countries through ACCESS ACCELERATED initiative.

